PCN141 USE OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN EVALUATING CANCER DRUGS IN ENGLAND

Abstract

Authors

Y. Yi S. Lucherini

Full Text Cite This Article
Back to Volume 22, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×